SlideShare uma empresa Scribd logo
1 de 24
Baixar para ler offline
Clinical Guidelines—
Lowering High Blood
Pressure in Adults
Hypertension
Scope

High Blood Pressure
(hypertension)
•is the most common
primary diagnosis in the
U.S.,
•affects approximately 1
in 3 adults in the U.S.,
and
•affects more than 65% of
people over 65 years old.



                            2
Hypertension
Effects
Hypertension can damage the

          Brain                   Heart
          It’s the most           It’s a major risk factor
          important risk factor   for heart attack and the
          for stroke.             #1 risk for congestive
                                  heart failure.

          Kidneys                 Arteries
          It can cause the        It’s associated with
          kidneys to fail,        stiffer arteries,
          resulting in dialysis   causing the heart and
          or a kidney             kidneys to work
          transplant.             harder.

                                                       3
Hypertension
Adults at Risk

Percentage of adults with hypertension by age




                                                4
Hypertension
Adults at Risk
Percentage of adults with hypertension by ethnicity




                                                      5
Hypertension
Adults at Risk

Percentage of
adults with
hypertension
by state




(Source: CDC Behavioral
Risk Factor Surveillance
System)



                           6
Blood Pressure
Know the Numbers




                   7
Blood Pressure
Cardiovascular Disease (CVD)

According to the 7th Report from the Joint National Committee
on Prevention, Detection, Evaluation, and Treatment of
High Blood Pressure (JNC7)

•BP relationship to risk of CVD is “continuous, consistent,
       and independent of other risk factors.”
•For people 40-70 years old, each increment of 20/10 mmHg
       doubles the risk of CVD across the entire BP range,
       starting from 115/75 mmHg.
•Hypertension can be prevented if prehypertension is
       discovered.


                                                          8
Blood Pressure
Benefits of Lowering

      Heart          Stroke    Myocardial
     Failure       Incidence   Infarction




                               (Source: JNC7)


                                                9
Hypertension
Evaluation

1. Assess lifestyle and identify major CVD risk factors or
   concomitant disorders that affect prognosis and
   guide treatment.

2. Identify causes of hypertension.

3. Assess the presence or absence of target organ
   damage and CVD.




                                                         10
Hypertension Evaluation
1. Assess Lifestyle & CVD Risk Factors


  Assess Lifestyle                   Identify CVD Risk Factors
  •Weight                            •Hypertension
  •Eating routine                    •Obesity
  •Sodium intake                     •Dyslipidemia
  •Physical activity                 •Diabetes mellitus
  •Alcohol consumption               •Microalbuminuria or estimated
  •Smoking habits                       glomerular filtration rate <60 ml/min
                                     •Age
                                     •Family history of premature CVD*




 *CVD is considered premature when it occurs in men <55 years and women age <65 years.


                                                                                   11
Hypertension Evaluation
2. Identify Causes of Hypertension

  Identify Causes of Hypertension
  •Sleep apnea
  •Drug-related causes
  •Chronic kidney disease (CKD)
  •Primary aldosteronism
  •Renovascular disease
  •Chronic steroid therapy and Cushing’s syndrome
  •Pheochromocytoma
  •Coarctation of the aorta
  •Thyroid or parathyroid disease




                                                    12
Hypertension Evaluation
3. Assess Presence of Target Organ Damage


      Brain                               Kidneys
  •       Stroke or transient             • CKD
          ischemic attack
                                          Arteries
      Heart                               •   Peripheral arterial
      •    Left ventricular hypertrophy       disease
      •    Angina or prior myocardial
           infarction                     Eyes
      •    Prior coronary
                                          • Retinopathy
           revascularization
      •    Heart failure



                                                                    13
Treatment
Goal of Therapy

• Reduce CVD and renal morbidity and mortality.

• Treat to BP <140/90 mmHg or BP <130/80 mmHg in
  patients with diabetes or CKD.

• Achieve the systolic BP (SBP) goal, which is especially
  important in persons ≥50 years old.




                                                            14
Treatment
Lifestyle Modification

Modify Lifestyle to             Reduce SBP approximately
•Reduce weight                  5-20 mmHg/10kg weight loss
•Adopt healthy eating plan      8-14 mmHg
•Reduce dietary sodium intake 2-8 mmHg
•Increase physical activity     4-9 mmHg
•Moderate alcohol intake        2-4 mmHg




                                                             15
Treatment
Pharmacological

•Lowering BP with several classes of drugs will reduce the


•Most hypertension patients will need two or more




 (*See algorithm for Treatment of Hypertension in the JNC7 report)



                                                                     16
Treatment
Other Considerations

• CVD risk factors should be treated and
  tobacco avoided.



• Low-dose aspirin therapy should be
  considered but only when BP is
  controlled (risk of hemorrhagic strokes
  increases in patients with uncontrolled
  hypertension).




                                            17
Care Management
Follow-Up

Patients should be checked:

•monthly for follow-up and
medication adjustment until BP goal
is reached
•more frequently for Stage 2
Hypertension or complicating
comorbid conditions
•1-2 times/year to check serum
potassium and creatinine
•every 3-6 months after BP is stable


                                       18
Care Management
Follow-Up
Additional factors that can affect how often patients should
follow-up with their physicians:

Comorbidities                 Other special considerations
•   Ischemic heart disease    •   Minorities
•   Heart failure             •   Obesity
•   Diabetic hypertension     •   Left ventricular hypertrophy
•   CKD                       •   Peripheral arterial disease
•   Cerebrovascular disease   •   Hypertension in older persons
                              •   Postural hypotension
Need for additional           •   Dementia
lab tests                     •   Gender and age
                              •   Urgencies and emergencies


                                                                  19
The Patient’s Choice

The patient must be
motivated to follow his/her
care management plan and
to establish and maintain a
healthy lifestyle.




                              20
The Patient’s Choice

Barriers to motivation
The patient might
•not understand the           •not afford the medication
condition or treatment        •not have transportation to
•deny the illness             appointments
•dislike taking medication
•feel uninvolved in his/her
healthcare plan
•feel uncomfortable talking
to the healthcare team



                                                        21
Patient Tools and Resources
For Motivation and Self-Management

Lifestyle Management
http://www.nhlbi.nih.gov/hbp/prevent/h_eating/h_eating.htm

Medications – Types & Tips
http://www.nhlbi.nih.gov/hbp/treat/treat.htm

Understanding Blood Pressure Readings
http://www.heart.org/HEARTORG/Conditions/HighBloodPressure/AboutHighBloodPressure/U
nderstanding-Blood-Pressure-Readings_UCM_301764_Article.jsp

HBP Risk Calculator
http://www.heart.org/HEARTORG/Conditions/HighBloodPressure/WhyBloodPressureMatters/
Assess-Your-High-Blood-Pressure-Related-Risks_UCM_301829_Article.jsp

HBP Tracker
http://www.heart.org/HEARTORG/Conditions/HighBloodPressure/HighBloodPressureToolsR
esources/Blood-Pressure-Trackers_UCM_303465_Article.jsp



                                                                                22
Contact

Sandy Pogones
spogones@primaris.org
314-374-6451




                        23
Resources

• The 7th Report of the Joint National Committee on
  Prevention, Detection, Evaluation, and Treatment of High
  Blood Pressure (JNC7)
• Million Hearts Blood Pressure Toolkit
• National Heart Lung and Blood Institute (NHLBI)
• NHLBI: Culturally Appropriate Education Materials




                                                         24

Mais conteúdo relacionado

Mais procurados

Hypertension, Non adherence to therapy
Hypertension, Non adherence to therapy Hypertension, Non adherence to therapy
Hypertension, Non adherence to therapy Ameel Yaqo
 
Hypertension in the Elderly
Hypertension in the ElderlyHypertension in the Elderly
Hypertension in the ElderlyMarc Evans Abat
 
Management of hypertension in elderly person.
Management of hypertension in elderly person.Management of hypertension in elderly person.
Management of hypertension in elderly person.Ramachandra Barik
 
Hypertension: New Concepts, Guidelines, and Clinical Management Hypertensio...
Hypertension: New Concepts, Guidelines, and Clinical Management 	 Hypertensio...Hypertension: New Concepts, Guidelines, and Clinical Management 	 Hypertensio...
Hypertension: New Concepts, Guidelines, and Clinical Management Hypertensio...MedicineAndFamily
 
Hipertensão Arterial - Slides da JNC7
Hipertensão Arterial - Slides da JNC7Hipertensão Arterial - Slides da JNC7
Hipertensão Arterial - Slides da JNC7semiologia
 
Hypertension
HypertensionHypertension
Hypertensionyuyuricci
 
Update in hypertension management
Update in hypertension managementUpdate in hypertension management
Update in hypertension managementTarek Khalil
 
Risk factors of cardiovascular
Risk factors of cardiovascularRisk factors of cardiovascular
Risk factors of cardiovascularDr Vaibhav Gupta
 
Hypertension: 2nd prevention
Hypertension: 2nd preventionHypertension: 2nd prevention
Hypertension: 2nd preventionSayed Sara
 
Risk assessment for cardiovascular disease prevention
Risk assessment for cardiovascular disease preventionRisk assessment for cardiovascular disease prevention
Risk assessment for cardiovascular disease preventionMohamed Badheeb
 
Epidemiology , diagnosis and treatment of Hypertension
Epidemiology , diagnosis and treatment of Hypertension Epidemiology , diagnosis and treatment of Hypertension
Epidemiology , diagnosis and treatment of Hypertension Toufiqur Rahman
 
Hypertension, Diabetes and Global HEARTS
Hypertension, Diabetes and Global HEARTSHypertension, Diabetes and Global HEARTS
Hypertension, Diabetes and Global HEARTSDr Arun More
 

Mais procurados (20)

Hypertension, Non adherence to therapy
Hypertension, Non adherence to therapy Hypertension, Non adherence to therapy
Hypertension, Non adherence to therapy
 
Hypertension & Diabetes
Hypertension & DiabetesHypertension & Diabetes
Hypertension & Diabetes
 
Hypertension in the Elderly
Hypertension in the ElderlyHypertension in the Elderly
Hypertension in the Elderly
 
Hypertension
Hypertension Hypertension
Hypertension
 
Management of hypertension in elderly person.
Management of hypertension in elderly person.Management of hypertension in elderly person.
Management of hypertension in elderly person.
 
Hypertension: New Concepts, Guidelines, and Clinical Management Hypertensio...
Hypertension: New Concepts, Guidelines, and Clinical Management 	 Hypertensio...Hypertension: New Concepts, Guidelines, and Clinical Management 	 Hypertensio...
Hypertension: New Concepts, Guidelines, and Clinical Management Hypertensio...
 
Joint National Committee
Joint National CommitteeJoint National Committee
Joint National Committee
 
Hypertension
HypertensionHypertension
Hypertension
 
Hipertensão Arterial - Slides da JNC7
Hipertensão Arterial - Slides da JNC7Hipertensão Arterial - Slides da JNC7
Hipertensão Arterial - Slides da JNC7
 
Hypertension
HypertensionHypertension
Hypertension
 
Update in hypertension management
Update in hypertension managementUpdate in hypertension management
Update in hypertension management
 
Risk factors of cardiovascular
Risk factors of cardiovascularRisk factors of cardiovascular
Risk factors of cardiovascular
 
Hypertension: 2nd prevention
Hypertension: 2nd preventionHypertension: 2nd prevention
Hypertension: 2nd prevention
 
Hypertension guidelines 2007
Hypertension guidelines 2007Hypertension guidelines 2007
Hypertension guidelines 2007
 
Hypertension (HTN)
Hypertension (HTN)Hypertension (HTN)
Hypertension (HTN)
 
Cardio awarness newer
Cardio awarness newerCardio awarness newer
Cardio awarness newer
 
Risk assessment for cardiovascular disease prevention
Risk assessment for cardiovascular disease preventionRisk assessment for cardiovascular disease prevention
Risk assessment for cardiovascular disease prevention
 
Hypertension Pro
Hypertension ProHypertension Pro
Hypertension Pro
 
Epidemiology , diagnosis and treatment of Hypertension
Epidemiology , diagnosis and treatment of Hypertension Epidemiology , diagnosis and treatment of Hypertension
Epidemiology , diagnosis and treatment of Hypertension
 
Hypertension, Diabetes and Global HEARTS
Hypertension, Diabetes and Global HEARTSHypertension, Diabetes and Global HEARTS
Hypertension, Diabetes and Global HEARTS
 

Destaque (7)

โปรแกรม Dreamweaver 8
โปรแกรม Dreamweaver 8โปรแกรม Dreamweaver 8
โปรแกรม Dreamweaver 8
 
Why does religiosity persist (sedikides 2010)
Why does religiosity persist (sedikides 2010)Why does religiosity persist (sedikides 2010)
Why does religiosity persist (sedikides 2010)
 
Processing
ProcessingProcessing
Processing
 
Religion explained (boyer 2001) ----- complete book
Religion explained (boyer 2001)  ----- complete bookReligion explained (boyer 2001)  ----- complete book
Religion explained (boyer 2001) ----- complete book
 
E teacher felder
E teacher felderE teacher felder
E teacher felder
 
Metrics shmetrics
Metrics shmetricsMetrics shmetrics
Metrics shmetrics
 
Marine Wharf East London +65 91898321
Marine Wharf East London +65 91898321Marine Wharf East London +65 91898321
Marine Wharf East London +65 91898321
 

Semelhante a Clinical Guidelines—Lowering High Blood Pressure

HTN Awareness Final.ppt
HTN Awareness Final.pptHTN Awareness Final.ppt
HTN Awareness Final.pptYasirMansoor6
 
Hypertension (HTN) - High Blood Pressure
Hypertension (HTN) - High Blood PressureHypertension (HTN) - High Blood Pressure
Hypertension (HTN) - High Blood PressureMd.Mahmudul Hasan Babor
 
PERCEPTIONS Vs REALITY: WOMEN AND HEART DISEASE
PERCEPTIONS Vs REALITY:WOMEN AND HEART DISEASEPERCEPTIONS Vs REALITY:WOMEN AND HEART DISEASE
PERCEPTIONS Vs REALITY: WOMEN AND HEART DISEASEHarilal Nambiar
 
Evaluation and management of hypertension
Evaluation and management of hypertensionEvaluation and management of hypertension
Evaluation and management of hypertensionNagesh Waghmare
 
BLOOD PRESSURE- WORLD HEALTH DAY 2013
BLOOD PRESSURE- WORLD HEALTH DAY 2013        BLOOD PRESSURE- WORLD HEALTH DAY 2013
BLOOD PRESSURE- WORLD HEALTH DAY 2013 Naveen Kumar
 
week 9 Assessment and Management of Patients with Hypertension- crisis.ppt
week 9 Assessment and Management of Patients with Hypertension- crisis.pptweek 9 Assessment and Management of Patients with Hypertension- crisis.ppt
week 9 Assessment and Management of Patients with Hypertension- crisis.pptAbdallahAlasal1
 
lincoln surgical presentation
lincoln surgical presentationlincoln surgical presentation
lincoln surgical presentationDaniel Le
 
Hypertension
Hypertension Hypertension
Hypertension Daniel Le
 
Diabetes management-and-the-elderly3461
Diabetes management-and-the-elderly3461Diabetes management-and-the-elderly3461
Diabetes management-and-the-elderly3461Buly Fatrahady
 
Hypertension-Eitiology of Hypertension.pdf
Hypertension-Eitiology of Hypertension.pdfHypertension-Eitiology of Hypertension.pdf
Hypertension-Eitiology of Hypertension.pdfhealthuseful
 
Hypertension
Hypertension  Hypertension
Hypertension Syed Raza
 

Semelhante a Clinical Guidelines—Lowering High Blood Pressure (20)

HTN Awareness Final.ppt
HTN Awareness Final.pptHTN Awareness Final.ppt
HTN Awareness Final.ppt
 
Hypertension.workshop.ncd
Hypertension.workshop.ncdHypertension.workshop.ncd
Hypertension.workshop.ncd
 
Hypertension (HTN) - High Blood Pressure
Hypertension (HTN) - High Blood PressureHypertension (HTN) - High Blood Pressure
Hypertension (HTN) - High Blood Pressure
 
PERCEPTIONS Vs REALITY: WOMEN AND HEART DISEASE
PERCEPTIONS Vs REALITY:WOMEN AND HEART DISEASEPERCEPTIONS Vs REALITY:WOMEN AND HEART DISEASE
PERCEPTIONS Vs REALITY: WOMEN AND HEART DISEASE
 
Evaluation and management of hypertension
Evaluation and management of hypertensionEvaluation and management of hypertension
Evaluation and management of hypertension
 
Hypertension
HypertensionHypertension
Hypertension
 
BLOOD PRESSURE- WORLD HEALTH DAY 2013
BLOOD PRESSURE- WORLD HEALTH DAY 2013        BLOOD PRESSURE- WORLD HEALTH DAY 2013
BLOOD PRESSURE- WORLD HEALTH DAY 2013
 
week 9 Assessment and Management of Patients with Hypertension- crisis.ppt
week 9 Assessment and Management of Patients with Hypertension- crisis.pptweek 9 Assessment and Management of Patients with Hypertension- crisis.ppt
week 9 Assessment and Management of Patients with Hypertension- crisis.ppt
 
lincoln surgical presentation
lincoln surgical presentationlincoln surgical presentation
lincoln surgical presentation
 
Hypertension
Hypertension Hypertension
Hypertension
 
Hypertension
HypertensionHypertension
Hypertension
 
Hypertension-ppt (1).pptx
Hypertension-ppt (1).pptxHypertension-ppt (1).pptx
Hypertension-ppt (1).pptx
 
Hypertension-ppt (1).pptx
Hypertension-ppt (1).pptxHypertension-ppt (1).pptx
Hypertension-ppt (1).pptx
 
Hypertension-ppt (1).pptx
Hypertension-ppt (1).pptxHypertension-ppt (1).pptx
Hypertension-ppt (1).pptx
 
Diabetes management-and-the-elderly3461
Diabetes management-and-the-elderly3461Diabetes management-and-the-elderly3461
Diabetes management-and-the-elderly3461
 
Hypertension
HypertensionHypertension
Hypertension
 
Pediatric hypertension
Pediatric hypertensionPediatric hypertension
Pediatric hypertension
 
Hypertension-Eitiology of Hypertension.pdf
Hypertension-Eitiology of Hypertension.pdfHypertension-Eitiology of Hypertension.pdf
Hypertension-Eitiology of Hypertension.pdf
 
Approach to a patient with resistant hypertension
Approach to a patient with resistant hypertensionApproach to a patient with resistant hypertension
Approach to a patient with resistant hypertension
 
Hypertension
Hypertension  Hypertension
Hypertension
 

Mais de learfieldinteraction

2018 Public Relations & Digital Reach Campaign for Missouri CTF
2018 Public Relations & Digital Reach Campaign for Missouri CTF2018 Public Relations & Digital Reach Campaign for Missouri CTF
2018 Public Relations & Digital Reach Campaign for Missouri CTFlearfieldinteraction
 
2016-2017 Public Relations & Digital Reach Campaign for Missouri CTF
2016-2017 Public Relations & Digital Reach Campaign for Missouri CTF2016-2017 Public Relations & Digital Reach Campaign for Missouri CTF
2016-2017 Public Relations & Digital Reach Campaign for Missouri CTFlearfieldinteraction
 
Pulic Relations & Digital Reach Campaign for Missouri CTF
Pulic Relations & Digital Reach Campaign for Missouri CTFPulic Relations & Digital Reach Campaign for Missouri CTF
Pulic Relations & Digital Reach Campaign for Missouri CTFlearfieldinteraction
 
Children's Trust Fund Child Abuse & Neglect Prevention Conference Program 2013
Children's Trust Fund Child Abuse & Neglect Prevention Conference Program 2013Children's Trust Fund Child Abuse & Neglect Prevention Conference Program 2013
Children's Trust Fund Child Abuse & Neglect Prevention Conference Program 2013learfieldinteraction
 
HIT Assistance Center Advanced Webinar
HIT Assistance Center Advanced WebinarHIT Assistance Center Advanced Webinar
HIT Assistance Center Advanced Webinarlearfieldinteraction
 
Colorectal Cancer: Putting Prevention into Practice
Colorectal Cancer: Putting Prevention into PracticeColorectal Cancer: Putting Prevention into Practice
Colorectal Cancer: Putting Prevention into Practicelearfieldinteraction
 
MU Testing to benefits of ShowMeVax
MU Testing to benefits of ShowMeVaxMU Testing to benefits of ShowMeVax
MU Testing to benefits of ShowMeVaxlearfieldinteraction
 
Meaningful Use Stage 2: What's Next?
Meaningful Use Stage 2: What's Next?Meaningful Use Stage 2: What's Next?
Meaningful Use Stage 2: What's Next?learfieldinteraction
 
MAFP Quality Reporting for Cash-CMS Incentives and Your Bottom Line
MAFP Quality Reporting for Cash-CMS Incentives and Your Bottom LineMAFP Quality Reporting for Cash-CMS Incentives and Your Bottom Line
MAFP Quality Reporting for Cash-CMS Incentives and Your Bottom Linelearfieldinteraction
 
Moving Forward with E-Prescribe-MOHIT
Moving Forward with E-Prescribe-MOHITMoving Forward with E-Prescribe-MOHIT
Moving Forward with E-Prescribe-MOHITlearfieldinteraction
 

Mais de learfieldinteraction (19)

2018 Public Relations & Digital Reach Campaign for Missouri CTF
2018 Public Relations & Digital Reach Campaign for Missouri CTF2018 Public Relations & Digital Reach Campaign for Missouri CTF
2018 Public Relations & Digital Reach Campaign for Missouri CTF
 
2016-2017 Public Relations & Digital Reach Campaign for Missouri CTF
2016-2017 Public Relations & Digital Reach Campaign for Missouri CTF2016-2017 Public Relations & Digital Reach Campaign for Missouri CTF
2016-2017 Public Relations & Digital Reach Campaign for Missouri CTF
 
Fighting Medicare Scams
Fighting Medicare ScamsFighting Medicare Scams
Fighting Medicare Scams
 
Pulic Relations & Digital Reach Campaign for Missouri CTF
Pulic Relations & Digital Reach Campaign for Missouri CTFPulic Relations & Digital Reach Campaign for Missouri CTF
Pulic Relations & Digital Reach Campaign for Missouri CTF
 
Children's Trust Fund Child Abuse & Neglect Prevention Conference Program 2013
Children's Trust Fund Child Abuse & Neglect Prevention Conference Program 2013Children's Trust Fund Child Abuse & Neglect Prevention Conference Program 2013
Children's Trust Fund Child Abuse & Neglect Prevention Conference Program 2013
 
MSMA New PQRS Regulations
MSMA New PQRS RegulationsMSMA New PQRS Regulations
MSMA New PQRS Regulations
 
HIT Assistance Center Advanced Webinar
HIT Assistance Center Advanced WebinarHIT Assistance Center Advanced Webinar
HIT Assistance Center Advanced Webinar
 
Transcription
Transcription Transcription
Transcription
 
Colorectal Cancer: Putting Prevention into Practice
Colorectal Cancer: Putting Prevention into PracticeColorectal Cancer: Putting Prevention into Practice
Colorectal Cancer: Putting Prevention into Practice
 
Patient Portals
Patient PortalsPatient Portals
Patient Portals
 
MU Testing to benefits of ShowMeVax
MU Testing to benefits of ShowMeVaxMU Testing to benefits of ShowMeVax
MU Testing to benefits of ShowMeVax
 
D4 Asprin Therapy
D4  Asprin TherapyD4  Asprin Therapy
D4 Asprin Therapy
 
Pneumococcal Vaccination
Pneumococcal Vaccination Pneumococcal Vaccination
Pneumococcal Vaccination
 
Disasster Recovery and HIT
Disasster Recovery and HITDisasster Recovery and HIT
Disasster Recovery and HIT
 
Meaningful Use Stage 2: What's Next?
Meaningful Use Stage 2: What's Next?Meaningful Use Stage 2: What's Next?
Meaningful Use Stage 2: What's Next?
 
Keep Your Practice Alive
Keep Your Practice AliveKeep Your Practice Alive
Keep Your Practice Alive
 
MAFP Quality Reporting for Cash-CMS Incentives and Your Bottom Line
MAFP Quality Reporting for Cash-CMS Incentives and Your Bottom LineMAFP Quality Reporting for Cash-CMS Incentives and Your Bottom Line
MAFP Quality Reporting for Cash-CMS Incentives and Your Bottom Line
 
Moving Forward with E-Prescribe-MOHIT
Moving Forward with E-Prescribe-MOHITMoving Forward with E-Prescribe-MOHIT
Moving Forward with E-Prescribe-MOHIT
 
Learfield InterAction
Learfield InterActionLearfield InterAction
Learfield InterAction
 

Último

Screening for colorectal cancer AAU.pptx
Screening for colorectal cancer AAU.pptxScreening for colorectal cancer AAU.pptx
Screening for colorectal cancer AAU.pptxtadehabte
 
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
PULMONARY EDEMA AND  ITS  MANAGEMENT.pdfPULMONARY EDEMA AND  ITS  MANAGEMENT.pdf
PULMONARY EDEMA AND ITS MANAGEMENT.pdfDolisha Warbi
 
Introduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiIntroduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiGoogle
 
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurMETHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurNavdeep Kaur
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisGolden Helix
 
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptxPresentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptxpdamico1
 
medico legal aspects of wound - forensic medicine
medico legal aspects of wound - forensic medicinemedico legal aspects of wound - forensic medicine
medico legal aspects of wound - forensic medicinethanaram patel
 
PHYSIOTHERAPY IN HEART TRANSPLANTATION..
PHYSIOTHERAPY IN HEART TRANSPLANTATION..PHYSIOTHERAPY IN HEART TRANSPLANTATION..
PHYSIOTHERAPY IN HEART TRANSPLANTATION..AneriPatwari
 
Tans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxTans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxKezaiah S
 
HERBS AS HEALTH FOOD - Brief introduction and therapeutic applications of: N...
HERBS AS HEALTH FOOD - Brief introduction and therapeutic applications of:  N...HERBS AS HEALTH FOOD - Brief introduction and therapeutic applications of:  N...
HERBS AS HEALTH FOOD - Brief introduction and therapeutic applications of: N...Divya Kanojiya
 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...sdateam0
 
Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.ANJALI
 
Informed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxInformed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxSasikiranMarri
 
Phytochemical Investigation of Drugs PDF.pdf
Phytochemical Investigation of Drugs PDF.pdfPhytochemical Investigation of Drugs PDF.pdf
Phytochemical Investigation of Drugs PDF.pdfDivya Kanojiya
 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptxBibekananda shah
 
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfLippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfSreeja Cherukuru
 
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
PNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdfPNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdf
PNEUMOTHORAX AND ITS MANAGEMENTS.pdfDolisha Warbi
 
epilepsy and status epilepticus for undergraduate.pptx
epilepsy and status epilepticus  for undergraduate.pptxepilepsy and status epilepticus  for undergraduate.pptx
epilepsy and status epilepticus for undergraduate.pptxMohamed Rizk Khodair
 
Valproic Acid. (VPA). Antiseizure medication
Valproic Acid.  (VPA). Antiseizure medicationValproic Acid.  (VPA). Antiseizure medication
Valproic Acid. (VPA). Antiseizure medicationMohamadAlhes
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPrerana Jadhav
 

Último (20)

Screening for colorectal cancer AAU.pptx
Screening for colorectal cancer AAU.pptxScreening for colorectal cancer AAU.pptx
Screening for colorectal cancer AAU.pptx
 
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
PULMONARY EDEMA AND  ITS  MANAGEMENT.pdfPULMONARY EDEMA AND  ITS  MANAGEMENT.pdf
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
 
Introduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiIntroduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali Rai
 
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurMETHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
 
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptxPresentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
 
medico legal aspects of wound - forensic medicine
medico legal aspects of wound - forensic medicinemedico legal aspects of wound - forensic medicine
medico legal aspects of wound - forensic medicine
 
PHYSIOTHERAPY IN HEART TRANSPLANTATION..
PHYSIOTHERAPY IN HEART TRANSPLANTATION..PHYSIOTHERAPY IN HEART TRANSPLANTATION..
PHYSIOTHERAPY IN HEART TRANSPLANTATION..
 
Tans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxTans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptx
 
HERBS AS HEALTH FOOD - Brief introduction and therapeutic applications of: N...
HERBS AS HEALTH FOOD - Brief introduction and therapeutic applications of:  N...HERBS AS HEALTH FOOD - Brief introduction and therapeutic applications of:  N...
HERBS AS HEALTH FOOD - Brief introduction and therapeutic applications of: N...
 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
 
Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.
 
Informed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxInformed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptx
 
Phytochemical Investigation of Drugs PDF.pdf
Phytochemical Investigation of Drugs PDF.pdfPhytochemical Investigation of Drugs PDF.pdf
Phytochemical Investigation of Drugs PDF.pdf
 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
 
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfLippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
 
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
PNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdfPNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdf
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
 
epilepsy and status epilepticus for undergraduate.pptx
epilepsy and status epilepticus  for undergraduate.pptxepilepsy and status epilepticus  for undergraduate.pptx
epilepsy and status epilepticus for undergraduate.pptx
 
Valproic Acid. (VPA). Antiseizure medication
Valproic Acid.  (VPA). Antiseizure medicationValproic Acid.  (VPA). Antiseizure medication
Valproic Acid. (VPA). Antiseizure medication
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous System
 

Clinical Guidelines—Lowering High Blood Pressure

  • 1. Clinical Guidelines— Lowering High Blood Pressure in Adults
  • 2. Hypertension Scope High Blood Pressure (hypertension) •is the most common primary diagnosis in the U.S., •affects approximately 1 in 3 adults in the U.S., and •affects more than 65% of people over 65 years old. 2
  • 3. Hypertension Effects Hypertension can damage the Brain Heart It’s the most It’s a major risk factor important risk factor for heart attack and the for stroke. #1 risk for congestive heart failure. Kidneys Arteries It can cause the It’s associated with kidneys to fail, stiffer arteries, resulting in dialysis causing the heart and or a kidney kidneys to work transplant. harder. 3
  • 4. Hypertension Adults at Risk Percentage of adults with hypertension by age 4
  • 5. Hypertension Adults at Risk Percentage of adults with hypertension by ethnicity 5
  • 6. Hypertension Adults at Risk Percentage of adults with hypertension by state (Source: CDC Behavioral Risk Factor Surveillance System) 6
  • 8. Blood Pressure Cardiovascular Disease (CVD) According to the 7th Report from the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC7) •BP relationship to risk of CVD is “continuous, consistent, and independent of other risk factors.” •For people 40-70 years old, each increment of 20/10 mmHg doubles the risk of CVD across the entire BP range, starting from 115/75 mmHg. •Hypertension can be prevented if prehypertension is discovered. 8
  • 9. Blood Pressure Benefits of Lowering Heart Stroke Myocardial Failure Incidence Infarction (Source: JNC7) 9
  • 10. Hypertension Evaluation 1. Assess lifestyle and identify major CVD risk factors or concomitant disorders that affect prognosis and guide treatment. 2. Identify causes of hypertension. 3. Assess the presence or absence of target organ damage and CVD. 10
  • 11. Hypertension Evaluation 1. Assess Lifestyle & CVD Risk Factors Assess Lifestyle Identify CVD Risk Factors •Weight •Hypertension •Eating routine •Obesity •Sodium intake •Dyslipidemia •Physical activity •Diabetes mellitus •Alcohol consumption •Microalbuminuria or estimated •Smoking habits glomerular filtration rate <60 ml/min •Age •Family history of premature CVD* *CVD is considered premature when it occurs in men <55 years and women age <65 years. 11
  • 12. Hypertension Evaluation 2. Identify Causes of Hypertension Identify Causes of Hypertension •Sleep apnea •Drug-related causes •Chronic kidney disease (CKD) •Primary aldosteronism •Renovascular disease •Chronic steroid therapy and Cushing’s syndrome •Pheochromocytoma •Coarctation of the aorta •Thyroid or parathyroid disease 12
  • 13. Hypertension Evaluation 3. Assess Presence of Target Organ Damage Brain Kidneys • Stroke or transient • CKD ischemic attack Arteries Heart • Peripheral arterial • Left ventricular hypertrophy disease • Angina or prior myocardial infarction Eyes • Prior coronary • Retinopathy revascularization • Heart failure 13
  • 14. Treatment Goal of Therapy • Reduce CVD and renal morbidity and mortality. • Treat to BP <140/90 mmHg or BP <130/80 mmHg in patients with diabetes or CKD. • Achieve the systolic BP (SBP) goal, which is especially important in persons ≥50 years old. 14
  • 15. Treatment Lifestyle Modification Modify Lifestyle to Reduce SBP approximately •Reduce weight 5-20 mmHg/10kg weight loss •Adopt healthy eating plan 8-14 mmHg •Reduce dietary sodium intake 2-8 mmHg •Increase physical activity 4-9 mmHg •Moderate alcohol intake 2-4 mmHg 15
  • 16. Treatment Pharmacological •Lowering BP with several classes of drugs will reduce the •Most hypertension patients will need two or more (*See algorithm for Treatment of Hypertension in the JNC7 report) 16
  • 17. Treatment Other Considerations • CVD risk factors should be treated and tobacco avoided. • Low-dose aspirin therapy should be considered but only when BP is controlled (risk of hemorrhagic strokes increases in patients with uncontrolled hypertension). 17
  • 18. Care Management Follow-Up Patients should be checked: •monthly for follow-up and medication adjustment until BP goal is reached •more frequently for Stage 2 Hypertension or complicating comorbid conditions •1-2 times/year to check serum potassium and creatinine •every 3-6 months after BP is stable 18
  • 19. Care Management Follow-Up Additional factors that can affect how often patients should follow-up with their physicians: Comorbidities Other special considerations • Ischemic heart disease • Minorities • Heart failure • Obesity • Diabetic hypertension • Left ventricular hypertrophy • CKD • Peripheral arterial disease • Cerebrovascular disease • Hypertension in older persons • Postural hypotension Need for additional • Dementia lab tests • Gender and age • Urgencies and emergencies 19
  • 20. The Patient’s Choice The patient must be motivated to follow his/her care management plan and to establish and maintain a healthy lifestyle. 20
  • 21. The Patient’s Choice Barriers to motivation The patient might •not understand the •not afford the medication condition or treatment •not have transportation to •deny the illness appointments •dislike taking medication •feel uninvolved in his/her healthcare plan •feel uncomfortable talking to the healthcare team 21
  • 22. Patient Tools and Resources For Motivation and Self-Management Lifestyle Management http://www.nhlbi.nih.gov/hbp/prevent/h_eating/h_eating.htm Medications – Types & Tips http://www.nhlbi.nih.gov/hbp/treat/treat.htm Understanding Blood Pressure Readings http://www.heart.org/HEARTORG/Conditions/HighBloodPressure/AboutHighBloodPressure/U nderstanding-Blood-Pressure-Readings_UCM_301764_Article.jsp HBP Risk Calculator http://www.heart.org/HEARTORG/Conditions/HighBloodPressure/WhyBloodPressureMatters/ Assess-Your-High-Blood-Pressure-Related-Risks_UCM_301829_Article.jsp HBP Tracker http://www.heart.org/HEARTORG/Conditions/HighBloodPressure/HighBloodPressureToolsR esources/Blood-Pressure-Trackers_UCM_303465_Article.jsp 22
  • 24. Resources • The 7th Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC7) • Million Hearts Blood Pressure Toolkit • National Heart Lung and Blood Institute (NHLBI) • NHLBI: Culturally Appropriate Education Materials 24